CA2989115C - Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders - Google Patents

Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders Download PDF

Info

Publication number
CA2989115C
CA2989115C CA2989115A CA2989115A CA2989115C CA 2989115 C CA2989115 C CA 2989115C CA 2989115 A CA2989115 A CA 2989115A CA 2989115 A CA2989115 A CA 2989115A CA 2989115 C CA2989115 C CA 2989115C
Authority
CA
Canada
Prior art keywords
substituted
therapeutically effective
effective amount
pterostilbene
nicotinamide riboside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989115A
Other languages
English (en)
French (fr)
Other versions
CA2989115A1 (en
Inventor
Eric Alexander Marcotulli
Daniel Antonio Alminana
Paul Michael Bowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elysium Health Inc
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of CA2989115A1 publication Critical patent/CA2989115A1/en
Application granted granted Critical
Publication of CA2989115C publication Critical patent/CA2989115C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2989115A 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders Active CA2989115C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173733P 2015-06-10 2015-06-10
US62/173,733 2015-06-10
PCT/US2016/019653 WO2016200447A1 (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Publications (2)

Publication Number Publication Date
CA2989115A1 CA2989115A1 (en) 2016-12-15
CA2989115C true CA2989115C (en) 2024-01-02

Family

ID=57503873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989115A Active CA2989115C (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Country Status (13)

Country Link
US (2) US11426398B2 (enExample)
EP (1) EP3307754B1 (enExample)
JP (1) JP2018517774A (enExample)
KR (1) KR20180021784A (enExample)
CN (1) CN107849083A (enExample)
AU (2) AU2016274126A1 (enExample)
CA (1) CA2989115C (enExample)
ES (1) ES2932801T3 (enExample)
MX (2) MX389207B (enExample)
RU (1) RU2017145692A (enExample)
TW (1) TWI725033B (enExample)
WO (1) WO2016200447A1 (enExample)
ZA (1) ZA201800056B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849083A (zh) 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
WO2018170389A1 (en) * 2017-03-17 2018-09-20 Elysium Health, Inc. Nicotinamide riboside for use in treating or preventing liver damage
US11129843B2 (en) * 2017-04-24 2021-09-28 Elysium Health, Inc. Treating and preventing kidney damage
ES3004332T3 (en) 2017-05-17 2025-03-12 Univ De Valencia Estudi General Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
CA3108015A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
WO2019079686A1 (en) * 2017-10-19 2019-04-25 Elysium Health, Inc. PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH TDP-43
WO2019108875A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating glaucoma
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
JP7580380B2 (ja) * 2019-02-26 2024-11-11 ウニベルシタット デ バレンシア―エストゥディ ジェネラル 運動ニューロン疾患を処置するための方法及び組成物
WO2020190703A1 (en) * 2019-03-21 2020-09-24 Elysium Health, Inc. Methods for wound treatment
CN113712193A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 修复皮肤系统的组合物制备方法及其用途
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
US20230270770A1 (en) * 2020-07-30 2023-08-31 Moises HERNANDEZ-VAZQUEZ Nutritional supplements for repairing muscle and defending against deterioration from human aging
EP4380577A1 (en) * 2021-08-02 2024-06-12 Nuvamid SA Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2007061798A2 (en) * 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
WO2012129499A1 (en) 2011-03-23 2012-09-27 The Regents Of The University Of California Treatment of inflammatory and infectious skin disorders
US8841350B2 (en) 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
JP6509844B2 (ja) * 2013-10-30 2019-05-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
RU2016149767A (ru) * 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
NZ735411A (en) * 2015-03-16 2021-07-30 Chromadex Inc Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
CN107849083A (zh) 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法

Also Published As

Publication number Publication date
MX389207B (es) 2025-03-20
AU2020286208B2 (en) 2022-11-10
AU2016274126A1 (en) 2018-01-18
CA2989115A1 (en) 2016-12-15
EP3307754B1 (en) 2022-09-14
RU2017145692A (ru) 2019-07-10
AU2020286208A1 (en) 2021-01-07
ES2932801T3 (es) 2023-01-26
JP2018517774A (ja) 2018-07-05
US11426398B2 (en) 2022-08-30
CN107849083A (zh) 2018-03-27
US20220362233A1 (en) 2022-11-17
EP3307754A1 (en) 2018-04-18
KR20180021784A (ko) 2018-03-05
RU2017145692A3 (enExample) 2019-07-31
MX2021012600A (es) 2021-11-12
EP3307754A4 (en) 2019-03-27
TWI725033B (zh) 2021-04-21
WO2016200447A1 (en) 2016-12-15
MX2017016024A (es) 2018-08-15
US12109206B2 (en) 2024-10-08
ZA201800056B (en) 2023-10-25
TW201713322A (zh) 2017-04-16
US20180353497A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
US12109206B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US11998561B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
BR112020024269A2 (pt) combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
US20240299364A1 (en) Magnesium biotinate compositions and methods of use
US20140112983A1 (en) Nitrite compositions and uses thereof
KR20160005356A (ko) 방사선완화 약제학적 제형
HK1254169A1 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK1254169B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
CN114712488B (zh) Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos
ES2753361T3 (es) Sulfonamida y profármacos de fumaratos de sulfinamida y su uso en el tratamiento de diversas enfermedades
HK40080329B (en) Pharmaceutical composition containing dorzagliatin and glucagon-like peptide-1 analog
US20130143962A1 (en) Adamantyl Derivatives as Therapeutic Agents
WO2020190703A1 (en) Methods for wound treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210126

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202